These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16188170)

  • 21. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs for the treatment of type 2 diabetes.
    Chowdhury TA; Hossain B
    Br J Hosp Med (Lond); 2007 Apr; 68(4):178-83. PubMed ID: 17465090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
    Barnett A; Allsworth J; Jameson K; Mann R
    Curr Med Res Opin; 2007 Jul; 23(7):1493-507. PubMed ID: 17559747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
    Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
    [No Abstract]   [Full Text] [Related]  

  • 26. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
    Weyer C; Maggs DG; Young AA; Kolterman OG
    Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The next generation of PPAR drugs: do we have the tools to find them?
    Shearer BG; Billin AN
    Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examining the safety of PPAR agonists - current trends and future prospects.
    Bortolini M; Wright MB; Bopst M; Balas B
    Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
    Ahrén B
    Expert Opin Investig Drugs; 2006 Apr; 15(4):431-42. PubMed ID: 16548792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral antidiabetic agents in type 2 diabetes.
    Levetan C
    Curr Med Res Opin; 2007 Apr; 23(4):945-52. PubMed ID: 17407651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
    Deacon CF
    Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.
    Cohen A; Horton ES
    Curr Med Res Opin; 2007 Apr; 23(4):905-17. PubMed ID: 17407648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multitargeted bioactive ligands for PPARs discovered in the last decade.
    Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
    Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapies for diabesity.
    Bailey CJ
    Curr Diab Rep; 2009 Oct; 9(5):360-7. PubMed ID: 19793506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational drug design and PPAR agonists.
    Perfetti R; D'Amico E
    Curr Diab Rep; 2005 Oct; 5(5):340-5. PubMed ID: 16188168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.